FOI release

Request for Information on the Discontinuation of DAA MK-3281 for my Master Thesis (KU)

Some or all of the information requested was not provided because we didn't hold it.

Case reference FOI2025/01260

Received 4 December 2025

Published 29 January 2026

Request

I am currently completing my thesis in collaboration with the Copenhagen Trial Unit (CTU). My research focuses on the development history and regulatory outcomes of direct-acting antivirals (DAAs) for chronic hepatitis C. As part of this project, I am examining the factors that have led to the discontinuation of certain DAA candidates during clinical development and comparing them with agents from the same therapeutic class that successfully reached or remained on the market. To support this analysis, I kindly request any available information regarding the discontinuation of the following DAA: MK-3281 I would be grateful for information specifically on: 1. The stage of development at which the compound was discontinued 2. The primary reason(s) for discontinuation (e.g., safety findings, efficacy results, pharmacokinetics, strategic or commercial considerations) 3. The approximate date when development was halted. This information will be used for academic research purposes in my Master thesis. I am happy to provide documentation confirming my student status, or supervisor confirmation upon request. Thank you very much for your time and assistance. Please let me know if there is a preferred contact or department for such requests.

Response

See attached

Documents

• FOI2025_01260 (redacted).pdf (589.3 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.